Evidence map›Paper›PMID 41955023›Full record

ArticleJournal of the American Society of Nephrology : JASN2026

Retinoic Acid Receptor Responder Protein 1 Promotes Tubular Fibrosis via the KH RNA Binding Domain Containing, Signal Transduction Associated 1/Steroid Receptor Coactivator/p-Signal Transducer and Activator of Transcription 3 Axis.

Lin Ye, Zhuoyuan Jiang, Yong Wu, Yao Zeng, Xiangjun Chen, Baiyu Feng, Lijun Yin, Yanan Gao, Weiming Xu, Shuxiang Yan and 4 more

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lin YeDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.ORCID 0000-0003-0392-915
Zhuoyuan JiangDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.
Yong WuDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.ORCID 0000-0001-5449-8375
Yao ZengDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.
Xiangjun ChenDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Metabolic Vascular Diseases Key Laboratory of Sichuan and Chongqing Province, Chongqing, China.
Baiyu FengDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.ORCID 0009-0000-7530-9051
Lijun YinDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.
Yanan GaoDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.
Weiming XuDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.
Shuxiang YanDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.
Yu LiDepartment of Nephrology, Zhongshan Hospital Xiamen University, Xiamen, China.
Jinshan WuDepartment of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0002-9168-1707
Qifu LiDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Metabolic Vascular Diseases Key Laboratory of Sichuan and Chongqing Province, Chongqing, China.
Anqun ChenDepartment of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, Institute of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, China.ORCID 0000-0003-3714-9469

Funding

Degree & Postgraduate Education Reform Project of Central South University NO. 2025JGB014National Natural Science Foundation of China NO. 82222013National Natural Science Foundation of China NO. 82470731the Key Program of the Natural Science Foundation of Human Province, China NO. 2025JJ30048Vicerrectoría de Investigación y Estudios de Posgrado, Benemérita Universidad Autónoma de Puebla NO. 2025JGYB031
6 · The paper itself

Abstract

key pointsRetinoic acid receptor responder protein 1 is upregulated in proximal tubular epithelial cells in CKD. Soluble retinoic acid receptor responder protein 1 drives fibrosis by binding KH RNA binding domain containing, signal transduction associated 1, recruiting steroid receptor coactivator kinase, and inducing signal transducer and activator of transcription 3 phosphorylation.

backgroundKidney fibrosis is a hallmark of CKD, yet its underlying mechanisms remain incompletely understood. Retinoic acid receptor responder protein 1 (RARRES1) is largely restricted to podocytes in healthy kidneys but was upregulated within the tubulointerstitium in CKD. However, its functional contribution to kidney fibrosis remains unclear.

methodsTo assess the link between tubulointerstitial RARRES1 expression, eGFR, and fibrosis severity in patients with CKD, we analyzed multiple clinical datasets. RARRES1 upregulation in proximal tubular epithelial cells was confirmed in human CKD samples by immunofluorescence and RNAscope assays. Kidney fibrosis was evaluated in proximal tubule-specific Rarres1 knockout mice and RARRES1-overexpressing mice after CKD induction, including unilateral ureteral obstruction and folic acid-induced nephropathy. Mechanistically, mass spectrometry and coimmunoprecipitation, combined with truncation mutants, uncovered interactions among soluble RARRES1, KH RNA binding domain containing, signal transduction associated 1 (KHDRBS1), steroid receptor coactivator (Src) kinase, and phosphorylated signal transducer and activator of transcription 3 (STAT3). Pharmacologic blockade of STAT3 or Src kinase was used to evaluate the reversal of RARRES1-induced fibrotic phenotype.

resultsMultiple datasets revealed that tubulointerstitial RARRES1 expression correlated with decreased eGFR and increased fibrosis severity in patients with CKD. Immunofluorescence and RNAscope confirmed RARRES1 upregulation specifically in proximal tubular epithelial cells in CKD. Proximal tubule-specific knockout of Rarres1 significantly attenuated kidney fibrosis in two independent CKD models. Conversely, RARRES1-overexpressing mice showed aggravated kidney fibrosis compared with controls in the unilateral ureteral obstruction model. Soluble RARRES1 was identified as the key pathogenic form, with its plasma levels correlating with declining kidney function in patients with CKD. Mechanistically, soluble RARRES1 bound KHDRBS1, recruited Src kinase, and induced STAT3 phosphorylation at Tyr705, leading to upregulation of profibrotic factors. Inhibition of STAT3 or Src kinase partially reversed the fibrotic phenotype induced by RARRES1 overexpression.

conclusionsOur findings demonstrated that RARRES1 played an important role in regulating kidney fibrosis through the KHDRBS1/Src/p-STAT3 signaling axis.

Indexed as

Kidney Tubules, ProximalRenal Insufficiency, ChronicRNA-Binding ProteinsSTAT3 Transcription FactorAnimalsFibrosisHumansMaleMiceMice, KnockoutPhosphorylationSignal TransductionUp-RegulationRNA-Binding ProteinsSTAT3 protein, humanSTAT3 Transcription FactorCKDfibrosiskidney tubule

Identifiers

PMID41955023
PMCPMC13567844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.